Not Yet Recruiting
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
NCT07307287
- Conditions
- Breast Diseases, Breast Neoplasms, Early Breast Cancer, +8 more
- Locations
-
Not specified